http://stm.sciencemag.org/content/8/358/358ra126?utm_campaign=toc_stm_2016-09-28&et_rid=33952789&et_cid=842820
You are currently viewing the abstract.
View Full Text
View Full Text
Via AAAS ID
This article is available to AAAS members. If you are a AAAS Member use your via AAAS ID and password to log in. Not a member? Click here to join.
Artery-saving fat
Although fatty foods often have a bad reputation when it comes to atherosclerosis, a study by Çimen et al.
identifies a type of fat that is not only harmless but also protective.
Palmitoleate is a lipid that can be produced directly by the human body
and is also found in a variety of foods, but only in small amounts.
Using human cells and mouse models, the authors demonstrate that
palmitoleate reduces metabolic stress in a variety of tissues as well as
in atherosclerotic plaques and thus decreases the severity of
atherosclerosis in mouse models.
Abstract
De
novo lipogenesis (DNL), the conversion of glucose and other substrates
to lipids, is often associated with ectopic lipid accumulation,
metabolic stress, and insulin resistance, especially in the liver.
However, organ-specific DNL can also generate distinct lipids with
beneficial metabolic bioactivity, prompting a great interest in their
use for the treatment of metabolic diseases. Palmitoleate (PAO), one
such bioactive lipid, regulates lipid metabolism in liver and improves
glucose utilization in skeletal muscle when it is generated de novo from
the obese adipose tissue. We show that PAO treatment evokes an overall
lipidomic remodeling of the endoplasmic reticulum (ER) membranes in
macrophages and mouse tissues, which is associated with resistance of
the ER to hyperlipidemic stress. By preventing ER stress, PAO blocks
lipid-induced inflammasome activation in mouse and human macrophages.
Chronic PAO supplementation also lowers systemic interleukin-1β (IL-1β)
and IL-18 concentrations in vivo in hyperlipidemic mice. Moreover, PAO
prevents macrophage ER stress and IL-1β production in atherosclerotic
plaques in vivo, resulting in a marked reduction in plaque macrophages
and protection against atherosclerosis in mice. These findings
demonstrate that oral supplementation with a product of DNL such as PAO
can promote membrane remodeling associated with metabolic resilience of
intracellular organelles to lipid stress and limit the progression of
atherosclerosis. These findings support therapeutic PAO supplementation
as a potential preventive approach against complex metabolic and
inflammatory diseases such as atherosclerosis, which warrants further
studies in humans.
No comments:
Post a Comment